PrescriptionGiant is a FREE prescription savings program that can save you up to 75% on your prescriptions with or without insurance!

Polatuzumab vedotin-piiq Injection

Actual product appearance may differ slightly.

Click the CARD below to print or take a screenshot on your mobile phone or tablet. There is no need to download another app!

If you would like to personalize your card enter your full name in the member name field below the card at this link and click the Update button.

Why is this medication prescribed?

Polatuzumab vedotin-piiq is a prescription medication used in the treatment of certain types of cancer. Specifically, it is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in combination with other agents.

The medication works by targeting and binding to CD79b, a protein found on the surface of B cells, which are a type of white blood cell. By doing so, it delivers a cytotoxic (cell-killing) agent directly to the cancer cells, helping to inhibit their growth and survival.

How should this medicine be used?

Polatuzumab vedotin-piiq is administered as an intravenous (IV) infusion, meaning it is injected directly into the bloodstream through a vein. The specific dosage, treatment schedule, and duration of therapy will be determined by the prescribing healthcare provider based on the patient’s individual condition and overall treatment plan.

Typically, Polatuzumab vedotin-piiq is used in combination with other medications for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The medication is usually administered in a clinical setting, such as a hospital or infusion center, by a healthcare professional experienced in the administration of cancer therapies.

Here are some general guidelines for the use of Polatuzumab vedotin-piiq:

  • Dosage and Schedule: The dosage and treatment schedule will be determined by the healthcare provider and may depend on factors such as the patient’s weight, overall health, and other medications being used in combination.
  • Administration: Polatuzumab vedotin-piiq is administered as an intravenous infusion over a specific period of time. The infusion process will be closely monitored by healthcare professionals.
  • Pre-treatment: Patients may be pre-treated with other medications to help minimize the risk of infusion-related reactions or other side effects.
  • Monitoring: Throughout the treatment course, patients will be closely monitored for any signs of adverse reactions or complications. Regular check-ups and laboratory tests may be conducted to assess the patient’s response to treatment.

It’s crucial for patients to follow the healthcare provider’s instructions and attend all scheduled appointments for proper monitoring and management of potential side effects. If you or someone you know is prescribed Polatuzumab vedotin-piiq, it’s important to communicate openly with the healthcare team about any concerns, side effects, or changes in health during the course of treatment.

Other uses for this medicine

Polatuzumab vedotin-piiq is primarily indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in combination with other medications. Its use in other medical conditions or for other purposes is generally not recommended unless specifically prescribed by a healthcare professional for an off-label use.

What special precautions should I follow?

Special precautions should be taken when using Polatuzumab vedotin-piiq, and patients should discuss their medical history and current medications with their healthcare provider before starting treatment. Here are some general precautions:

  • Infusion Reactions: Infusion-related reactions, including fever, chills, and difficulty breathing, may occur during or after the administration of Polatuzumab vedotin-piiq. Healthcare providers often take precautions, such as pre-medications, to minimize the risk of these reactions.
  • Infections: This medication may increase the risk of infections. Patients should promptly report any signs of infection, such as fever, to their healthcare provider.
  • Hepatotoxicity: Polatuzumab vedotin-piiq can cause liver problems, and liver function should be monitored regularly. Patients should report any signs of liver dysfunction, such as yellowing of the skin or eyes, dark urine, or abdominal pain.
  • Peripheral Neuropathy: This medication may cause peripheral neuropathy, leading to symptoms such as numbness, tingling, or pain in the extremities. Patients should report any neurological symptoms to their healthcare provider.
  • Pregnancy and Breastfeeding: Polatuzumab vedotin-piiq may harm an unborn baby, so it is not recommended during pregnancy. Women of childbearing potential should use effective contraception during treatment and for a certain period afterward. Breastfeeding is not recommended during treatment and for some time after the last dose.
  • Other Medications: Patients should inform their healthcare provider about all prescription and over-the-counter medications, vitamins, and herbal supplements they are taking. Certain medications may interact with Polatuzumab vedotin-piiq.

It’s important for patients to attend all scheduled appointments, follow their healthcare provider’s instructions, and communicate any concerns or side effects promptly. This information is a general overview, and individual patient circumstances may vary, so it’s crucial to consult with a healthcare professional for personalized advice and guidance.

What special dietary instructions should I follow?

There are no specific dietary restrictions associated with Polatuzumab vedotin-piiq. However, maintaining a healthy and balanced diet is generally advisable for overall well-being during cancer treatment. Patients should discuss any specific dietary concerns or recommendations with their healthcare provider or a registered dietitian.

What should I do if I forget a dose?

Since Polatuzumab vedotin-piiq is administered by healthcare professionals in a clinical setting, patients typically do not need to worry about missing a dose. If you have any concerns or questions about the dosing schedule, it is crucial to contact your healthcare provider promptly for guidance. Adhering to the prescribed treatment plan is important for the effectiveness of the medication and the management of your medical condition.

What side effects can this medication cause?

Polatuzumab vedotin-piiq, like many medications, can cause side effects. It’s important to note that not all individuals will experience these side effects, and their severity can vary. Additionally, the combination therapy used alongside Polatuzumab vedotin-piiq may contribute to the overall side effect profile. Common side effects and adverse reactions associated with Polatuzumab vedotin-piiq include:

  • Infusion-Related Reactions: These may include fever, chills, nausea, fatigue, headache, and breathing difficulties during or after the infusion.
  • Cytopenias: This refers to a decrease in the number of blood cells. Patients may experience low levels of white blood cells, red blood cells, and platelets, which can lead to an increased risk of infections, anemia, and bleeding.
  • Peripheral Neuropathy: Numbness, tingling, or pain in the hands or feet may occur due to nerve damage.
  • Fatigue: Persistent tiredness or weakness is a common side effect.
  • Nausea: Some patients may experience nausea or vomiting.
  • Diarrhea: Diarrhea can occur as a side effect of Polatuzumab vedotin-piiq.
  • Fever: Elevated body temperature may occur.
  • Decreased Appetite: Some individuals may experience a reduced appetite.
  • Increased Liver Enzymes: Elevated levels of liver enzymes may be observed in blood tests, indicating potential liver problems.
  • Peripheral Edema: Swelling of the hands or feet may occur.
  • Pneumonia: Infections, including pneumonia, may occur.
  • Rash: Skin reactions, including rashes, may occur.

It’s important for patients to promptly report any unusual or severe side effects to their healthcare provider. The healthcare team will monitor for side effects during treatment and may take steps to manage or alleviate symptoms. In some cases, treatment may need to be adjusted or temporarily halted.

This is not an exhaustive list of side effects, and individual experiences may vary. Patients should consult their healthcare provider for a comprehensive understanding of potential side effects, and they should seek medical attention if they experience any concerning symptoms during or after Polatuzumab vedotin-piiq treatment.

What should I know about storage and disposal of this medication?

Storage and Disposal of Polatuzumab Vedotin-piiq:

  • Storage: Polatuzumab vedotin-piiq is typically stored by healthcare professionals in a clinical setting, such as a hospital or infusion center, where proper storage conditions can be maintained. If you are given the medication to take home for any reason, follow the specific storage instructions provided by your healthcare provider or pharmacist.
  • Disposal: Proper disposal of unused or expired medications is essential to prevent accidental exposure. Healthcare providers or pharmacists will handle the disposal of unused Polatuzumab vedotin-piiq in a healthcare facility. Do not attempt to dispose of this medication on your own.

In case of emergency/overdose

In the event of an emergency or suspected overdose, it is crucial to seek immediate medical attention. Symptoms of an overdose or severe reaction may include severe infusion reactions, increased risk of infections, cytopenias (low blood cell counts), and other adverse effects.

Contact your local emergency services or go to the nearest emergency room. Always carry information about the medications you are receiving, including the name of Polatuzumab vedotin-piiq, the dosage, and the prescribing healthcare provider’s contact information.

What other information should I know?

  • Regular Monitoring: During Polatuzumab vedotin-piiq treatment, you will undergo regular monitoring, including blood tests and clinical assessments. Attend all scheduled appointments to ensure proper monitoring of your health and response to treatment.
  • Communication with Healthcare Provider: Keep an open line of communication with your healthcare provider. Report any side effects, changes in symptoms, or concerns promptly.
  • Pregnancy and Breastfeeding: Inform your healthcare provider if you are pregnant, planning to become pregnant, or breastfeeding. Polatuzumab vedotin-piiq may harm an unborn baby, and its use is generally not recommended during pregnancy.
  • Other Medications and Supplements: Inform your healthcare provider about all medications, including prescription and over-the-counter drugs, vitamins, and herbal supplements you are taking. Certain medications may interact with Polatuzumab vedotin-piiq.
  • Medical History: Provide a comprehensive medical history to your healthcare provider, including any pre-existing conditions or prior treatments.
  • Follow-up Care: After completing the prescribed course of Polatuzumab vedotin-piiq, follow any post-treatment care instructions provided by your healthcare provider. This may include ongoing monitoring for potential late or long-term effects.

Always follow the guidance and instructions of your healthcare provider regarding the use, storage, and disposal of Polatuzumab vedotin-piiq. Individual circumstances may vary, and your healthcare provider is the best source of information for your specific situation.

Copyright © 2023